Natural Innate and Adaptive Immunity to Cancer

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Annual Review of Immunology (Impact Factor: 39.33). 04/2010; 29(1):235-71. DOI: 10.1146/annurev-immunol-031210-101324
Source: PubMed


The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against cancer. Recently, data obtained from numerous investigations in mouse models of cancer and in humans with cancer offer compelling evidence that particular innate and adaptive immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor-suppressor mechanisms. However, the immune system can also promote tumor progression. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. In this review, we discuss the current experimental and human clinical data supporting a cancer immunoediting process that provide the fundamental basis for further study of immunity to cancer and for the rational design of immunotherapies against cancer.

Full-text preview

Available from:
  • Source
    • "Likewise , mRNA levels of Ifit1 and Ifit2 , two type I IFN - stimulated genes ( ISGs ) , were also elevated in Ptgs2 À / À tumors ( Figure 2D ) , indicative of enhanced type I interferon ( IFN - a / b ) signaling , which is central to immune - mediated tumor control ( Gajewski et al . , 2013 ; Vesely et al . , 2011 ) . We failed to detect a reduction in the expression of type 2 cytokines , such as IL - 4 , IL - 5 , or IL - 13 , or markers associated with M2 macrophage polarization , such as iNOS , arginase I , Gas - 3 , or E - cadherin ( Figure S5 ; data not shown ) , despite the fact that they have been reported to be induced by prostanoids withi"
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity remain incompletely understood. Here, we show that the growth of tumors formed by mutant Braf(V600E) mouse melanoma cells in an immunocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tumor-promoting inflammation. Genetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways. This mouse COX-dependent inflammatory signature is remarkably conserved in human cutaneous melanoma biopsies, arguing for COX activity as a driver of immune suppression across species. Pre-clinical data demonstrate that inhibition of COX synergizes with anti-PD-1 blockade in inducing eradication of tumors, implying that COX inhibitors could be useful adjuvants for immune-based therapies in cancer patients.
    Cell 09/2015; 162(6). DOI:10.1016/j.cell.2015.08.015 · 32.24 Impact Factor
  • Source
    • "Complementary and alternative medical therapies such as those using fungal products (extracts and powders) can be a common practice to treat cancer patients receiving conventional anti-cancer treatments (Mueller et al., 2008; Wasser, 2002, 2014). There is evidence that the innate and adaptive immune responses of hosts play an important role in preventing tumors (Vesely et al., 2011) and that immunotherapy has become an important treatment for cancers (Dougan and Dranoff, 2009). Immuno-stimulation via the targeting of pattern recognition receptors (PRR's) on immune cells is an attractive approach in cancer immunotherapy (Goutagny et al., 2012), and agonists that target these receptors have clinically been investigated for their antitumor activities (Kaczanowska et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fungal β-D-glucans of the (1→3)-type are known to exhibit direct antitumor effects, and can also indirectly decrease tumor proliferation through immunomodulatory responses. The underlying molecular mechanisms involved in decreasing tumor formation, however, are not well understood. In this study, we examined the antiproliferative role and mechanism of action of three different fungal exocellular β-glucans in MCF-7 breast cancer cells. The β-glucans were obtained from Botryosphaeria rhodina MAMB-05 [two botryosphaerans; (1→3)(1→6)-β-D-glucan; one produced on glucose, the other on fructose] and Lasiodiplodia theobromae MMPI [lasiodiplodan; (1→6)-β-D-glucan, produced on glucose]. Using the cell proliferation-MTT assay, we showed that the β-glucans exhibited a time- and concentration-dependent antiproliferative activity (IC50, 100μg/ml). Markers of cell cycle, apoptosis, necrosis and oxidative stress were analyzed using flow cytometry, RT-PCR and Western blotting. Exposure to β-glucans increased apoptosis, necrosis, oxidative stress, mRNA expression of p53, p27 and Bax; the activity of AMP-activated protein-kinase, Forkhead transcription factor FOXO3a, Bax and caspase-3; and decreased the activity of p70S6K in MCF-7 cells. In the presence of hydrogen peroxide, the fungal β-glucans increased oxidative stress, which was associated with reduced cell viability. We showed that these β-glucans exhibited an antiproliferative effect that was associated with apoptosis, necrosis and oxidative stress. This study demonstrated for the first time that the apoptosis induced by β-glucans was mediated by AMP-activated protein-kinase and Forkhead transcription factor, FOXO3a. Our findings provide novel mechanistic insights into their antiproliferative roles, and compelling evidence that these β-glucans possess a broad range of biomodulatory properties that may prove useful in cancer treatment. Copyright © 2015. Published by Elsevier Ltd.
    The International Journal of Biochemistry & Cell Biology 08/2015; 67. DOI:10.1016/j.biocel.2015.08.003 · 4.05 Impact Factor
  • Source
    • "For patients with advanced and/ or high-grade disease, chemotherapy reduces recurrence outside the pelvis by 5%, but has no effect on survival (Johnson et al, 2011). Many studies show a relationship between tumour-infiltrating lymphocytes (TILs) and cancer behaviour (Kondratiev et al, 2004; Chang et al, 2005; Galon et al, 2006; de Jong et al, 2009; Leffers et al, 2009; Gooden et al, 2011; Schreiber et al, 2011; Vesely et al, 2011). In a cohort of 90 EC patients, Kondratiev et al (2004) described that low numbers of cytotoxic T cells (CTLs) was related to poor prognosis (hazard ratio (HR) 2.79). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adjuvant therapy increases disease-free survival in endometrial cancer (EC), but has no impact on overall survival and negatively influences the quality of life. We investigated the discriminatory power of classical and immunological predictors of recurrence in a cohort of EC patients and confirmed the findings in an independent validation cohort. We reanalysed the data from 355 EC patients and tested our findings in an independent validation cohort of 72 patients with EC. Predictors were selected and Harrell's C-index for concordance was used to determine discriminatory power for disease-free survival in the total group and stratified for histological subtype. Predictors for recurrence were FIGO stage, lymphovascular space invasion and numbers of cytotoxic and memory T-cells. For high risk cancer, cytotoxic or memory T-cells predicted recurrence as well as a combination of FIGO stage and lymphovascular space invasion (C-index 0.67 and 0.71 vs 0.70). Recurrence was best predicted when FIGO stage, lymphovascular space invasion and numbers of cytotoxic cells were used in combination (C-index 0.82). Findings were confirmed in the validation cohort. In high-risk EC, clinicopathological or immunological variables can predict regional or distant recurrence with equal accuracy, but the use of these variables in combination is more powerful.British Journal of Cancer advance online publication, 28 July 2015; doi:10.1038/bjc.2015.268
    British Journal of Cancer 07/2015; 113(5). DOI:10.1038/bjc.2015.268 · 4.84 Impact Factor
Show more